Mirabella Financial Services LLP Makes New Investment in Bristol-Myers Squibb (NYSE:BMY)

Mirabella Financial Services LLP bought a new stake in shares of Bristol-Myers Squibb (NYSE:BMY) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 29,914 shares of the biopharmaceutical company’s stock, valued at approximately $1,692,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Morse Asset Management Inc increased its holdings in Bristol-Myers Squibb by 25.0% in the third quarter. Morse Asset Management Inc now owns 10,000 shares of the biopharmaceutical company’s stock valued at $517,000 after buying an additional 2,000 shares during the last quarter. Tudor Financial Inc. acquired a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $250,000. Pine Valley Investments Ltd Liability Co increased its holdings in shares of Bristol-Myers Squibb by 1.3% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 44,897 shares of the biopharmaceutical company’s stock valued at $2,323,000 after acquiring an additional 575 shares during the last quarter. World Investment Advisors LLC raised its position in shares of Bristol-Myers Squibb by 18.7% during the 3rd quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company’s stock valued at $2,282,000 after acquiring an additional 6,954 shares in the last quarter. Finally, Arvest Bank Trust Division bought a new position in Bristol-Myers Squibb during the third quarter worth $1,724,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The shares were bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.07% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

BMY has been the subject of several recent research reports. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday, February 7th. Truist Financial increased their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. UBS Group decreased their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Cantor Fitzgerald increased their price target on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $57.67.

Bristol-Myers Squibb Trading Down 0.3 %

Shares of NYSE:BMY opened at $49.24 on Monday. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of $100.18 billion, a PE ratio of -11.14, a P/E/G ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The firm has a fifty day moving average price of $56.98 and a 200 day moving average price of $56.68.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.04%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.